Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. The agreement also includes a new tranche of €5 million made available at closing by Kartesia for the general corporate purposes of ADL, a commitment by the shareholders to approve a capital increase of at least €10 million to be completed before year-end, pro rata of the stake of each party, and the A&E (an amend and extend facility) of the senior financing. With immediate effect, ADL Biopharma will operate as an independent entity from ADL Bionatur Solutions. The Board of Directors has been expanded to 5 seats with the appointment of 3 new independent Directors: Raúl Crespo (Deloitte, Oquendo, KPMG), Ignacio Urbelz (Calidad Pascual, Vivesoy, HP) and Mirco Iwan (Capua Bioservices, Eismann), adding relevant expertise in key areas such as finance, operations and sales. Kartesia Advisor LLP completed the acquisition of 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. Víctor Xercavins, Javier Alós and Beatriz Causapé of Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor to ADL Biopharma and Linklaters, S.L.P. acted as legal advisor to Kartesia Advisor LLP.